Table 1.
The relationship between expressions of CD163 and clinicopathologic features of TNBC patients
| n (%) | High CD163 (%) | Low CD163 (%) | χ2-value | P | |
|---|---|---|---|---|---|
| Age (yr) | 0.614 | 0.432 | |||
| ≤35 | 20 (22.0) | 11 (52.4) | 9 (47.6) | ||
| >35 | 71 (78.0) | 32 (45.7) | 39 (54.3) | ||
| Menstrual status | 0.367 | 0.544 | |||
| Pre-menopause | 39 (42.9) | 17 (43.6) | 22 (56.4) | ||
| Post-menopause | 52 (57.1) | 26 (50.0) | 26 (50.0) | ||
| Tumor Stage before NAC | 4.586 | 0.032 | |||
| cT1-cT2 | 57 (62.6) | 22 (38.6) | 35 (61.4) | ||
| cT3-cT4 | 34 (37.4) | 21 (61.8) | 13 (38.2) | ||
| Histological grade | 4.357 | 0.037 | |||
| 1/2 | 35 (38.5) | 12 (34.3) | 23 (65.3) | ||
| 3 | 56 (61.5) | 31 (55.4) | 25 (44.6) | ||
| Histological type | 0.265 | 0.607 | |||
| Ductal | 78 (85.7) | 36 (46.2) | 42 (53.8) | ||
| Others | 13 (14.3) | 7 (53.8) | 6 (46.2) | ||
| LVI | 4.612 | 0.032 | |||
| Negative | 53 (58.2) | 20 (37.7) | 33 (62.3) | ||
| Positive | 38 (41.8) | 23 (60.5) | 15 (39.5) | ||
| Nodal status before NAC | 5.968 | 0.015 | |||
| Negative | 33 (36.3) | 10 (30.3) | 23 (69.7) | ||
| Positive | 58 (63.7) | 33 (56.9) | 25 (43.1) | ||
| Ki67 | 3.705 | 0.054 | |||
| <14 | 28 (30.8) | 9 (32.1) | 19 (67.9) | ||
| ≥14 | 63 (69.2) | 34 (54.0) | 29 (46.0) | ||
| NAC regimen | 0.625 | 0.732 | |||
| EC-T | 19 (20.9) | 10 (52.6) | 9 (47.4) | ||
| TEC | 59 (64.8) | 28 (49.2) | 31 (50.8) | ||
| PE | 13 (14.3) | 5 (38.5) | 8 (61.5) | ||
| pCR with NAC | 8.676 | 0.003 | |||
| Yes | 31 (34.1) | 8 (25.8) | 23 (74.2) | ||
| No | 60 (75.9) | 35 (58.3) | 25 (41.7) | ||
| Surgery | 0.214 | 0.644 | |||
| Mastectomy | 57 (62.6) | 28 (49.1) | 29 (50.9) | ||
| BCS | 34 (37.4) | 15 (44.1) | 19 (55.9) | ||
NAC: neoadjuvant chemotherapy; LVI: lymphovascular invasion; EC-T: epirubicin, cyclophosphamide, docetaxel; TEC: docetaxel, cyclophosphamide, epirubicin PE: paclitaxel, epirubicin; pCR: pathological complete response; BCS: breast-conserving surgery.